any other phenotype (Hot/Hot, Cold/Hot, Cold/Cold) had a much lower potential for thyroid malignancy, and therefore, it may be appropriate to treat these patients with close follow-up rather than FNAB or thyroid resection.
Onkendi et al. further identified a group of patients who were found during surgery to have a false-positive imaging result, characterized by a Hot/Cold scan with no abnormal parathyroid found corresponding to the imaging localization. Patients with underlying thyroid malignancy were more likely to have a false-positive parathyroid scintigraphy (45% compared to 22% of patients with benign thyroid disease). These data indicate that patients undergoing neck exploration who are found to have a false-positive dual imaging result should have further intraoperative evaluation for the potential of an undiagnosed thyroid malignancy.
Management of patients with PHPT and concurrent thyroid disease is an evolving field. Onkendi et al. provide useful information to identify patients requiring further assessment of concurrent thyroid nodules. However, because of the significant cost and logistics of using the I-123 isotope, many imaging protocols for PHPT do not utilize I-123 subtraction. For example, other protocols for parathyroid localization include the use of MIBI-pertechnetate subtraction scintigraphy. High-resolution ultrasound is also commonly used to localize abnormal parathyroid glands and is particularly valuable for identifying thyroid nodules. Both MIBI-pertechnetate scintigraphy and neck ultrasound can identify concurrent thyroid nodules requiring further evaluation with FNAB, and these other imaging modalities have the potential to identify a concurrent thyroid malignancy. 1, 6 Interpretation of parathyroid imaging tests can be used to stratify patients with PHPT and thyroid disease according to risk for thyroid malignancy. Further studies are warranted to more clearly define how various parathyroid localization techniques should be interpreted with regard to concurrent thyroid pathology.
